| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Nottingham, UK—Today Sygnature Discovery, a drug discovery and preclinical services company, announced a collaboration with SilcsBio, a software company focused on high-throughput fully atomistic simulations of protein targets and protein-ligand structures. SilcsBio has provided Sygnature with access to its SILCS (Site Identification by Ligand Competitive Saturation) and SSFEP (Single Step Free Energy Perturbation) software. Sygnature will now able to offer clients the benefits of these techniques in their drug discovery projects.
 
The SILCS software identifies binding site hot spots on a protein’s surface. This could, potentially, include “cryptic pockets” – binding sites for which little structural information is available. SILCS methodology involves performing molecular dynamics simulations on a protein in an aqueous solution of chemically diverse small molecules. This generates probability distributions of fragment types, termed FragMaps.
 
These FragMaps can be used rapidly and with minimal computational expense to predict or refine ligand binding poses, quantitatively score ligands in the binding pocket and generate multiple receptor-based pharmacophore models for use in virtual screening campaigns. This has been shown to be a more effective technique than standard docking studies or receptor-based pharmacophore modeling.
 
“SilcsBio software suite, with its robust physics-based algorithms and user-friendly interface, provides great leverage in the structure-based drug design area and enables us to rapidly validate new ideas/hypothesis,” said Bill Tatsis, computational chemist at Sygnature Discovery.
 
In a complementary manner, the SSFEP software has demonstrated success in ranking compound binding affinities to target proteins. In particular, the SSFEP approach is about 1000-fold faster than the more widely used FEP methodology. It achieves this speed by post-processing molecular dynamics simulation data of a ligand, and using it to estimate the alchemical free energy change of chemically modifying that ligand.
 
Such a rapid assessment of the drug design team’s ideas could be advantageous in speeding up the design-test-optimize cycle. Being able to evaluate and prioritize design ideas in just a few days can have a significant impact in structure-based design projects.
 
In the past six months, Sygnature has applied the SilcsBio software suite successfully in various hit-to-lead and lead optimization projects. The company believes these new software tools will offer substantial benefits to its customers, not least because of the time savings the software can provide.
 
“We’re delighted to be collaborating with Sygnature Discovery to bring the advantages of our drug design software to Sygnature’s projects and customers,” mentioned Ken Malone, chief executive officer of SilcsBio. “This collaboration is very meaningful to us as Sygnature continues to be a great partner and it opens the door to new markets for SilcsBio.”

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue